Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
Rapport
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • The company is one of the best yield companies with high dividend expectations.
  • The stock is in a well-established, long-term rising trend above the technical support level at 76.55 CHF
Weaknesses
  • Technically, the stock approaches a strong medium-term resistance at CHF 84.65.
  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
  • The company's enterprise value to sales, at 4.51 times its current sales, is high.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
NOVARTIS13.50%226 453
JOHNSON & JOHNSON22.11%377 585
ROCHE HOLDING LTD.5.55%215 760
PFIZER10.31%213 372
MERCK AND COMPANY7.88%173 214
AMGEN27.41%135 924
SANOFI9.90%125 891
BAYER19.94%115 989
CELGENE CORPORATION18.51%107 315
BRISTOL-MYERS SQUIBB COMPAN..9.00%104 463
GLAXOSMITHKLINE-1.82%99 651
NOVO NORDISK A/S22.22%98 848
ABBOTT LABORATORIES45.20%96 897
ELI LILLY AND COMPANY16.56%94 388
ASTRAZENECA16.64%86 419
ALLERGAN PLC-10.89%62 565
More Results
Financials ($)
Sales 2017 48 803 M
EBIT 2017 11 558 M
Net income 2017 7 295 M
Debt 2017 17 704 M
Yield 2017 3,30%
P/E ratio 2017 25,45
P/E ratio 2018 21,73
EV / Sales 2017 4,97x
EV / Sales 2018 4,75x
Capitalization 225 B
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart NOVARTIS
Duration : Period : Day
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Duration : Period : Week
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders